 Gregory Kinney
Concepts (389)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 52 | 2024 | 1130 | 5.610 |
Why?
| | Coronary Artery Disease | 27 | 2023 | 648 | 1.970 |
Why?
| | Tomography, X-Ray Computed | 40 | 2023 | 2433 | 1.790 |
Why?
| | Diabetes Mellitus, Type 1 | 37 | 2022 | 3358 | 1.720 |
Why?
| | Smokers | 16 | 2023 | 149 | 1.620 |
Why?
| | Smoking | 25 | 2023 | 1478 | 1.500 |
Why?
| | Cannabis | 8 | 2023 | 381 | 1.460 |
Why?
| | Forced Expiratory Volume | 24 | 2024 | 520 | 1.240 |
Why?
| | Pulmonary Emphysema | 11 | 2023 | 318 | 1.210 |
Why?
| | Bronchiectasis | 7 | 2023 | 105 | 1.130 |
Why?
| | Calcinosis | 17 | 2015 | 282 | 1.030 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 526 | 0.950 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 168 | 0.920 |
Why?
| | Hyperlipidemias | 2 | 2023 | 127 | 0.910 |
Why?
| | Lung | 20 | 2023 | 3623 | 0.870 |
Why?
| | Marijuana Smoking | 3 | 2022 | 220 | 0.870 |
Why?
| | Dronabinol | 3 | 2021 | 120 | 0.860 |
Why?
| | Cardiovascular System | 1 | 2023 | 127 | 0.850 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 261 | 0.740 |
Why?
| | Volatilization | 1 | 2019 | 65 | 0.720 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2159 | 0.700 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 80 | 0.700 |
Why?
| | Middle Aged | 79 | 2023 | 27510 | 0.700 |
Why?
| | Cannabinoids | 4 | 2023 | 115 | 0.680 |
Why?
| | Spirometry | 14 | 2024 | 262 | 0.620 |
Why?
| | Coronary Vessels | 7 | 2021 | 233 | 0.600 |
Why?
| | Risk Factors | 35 | 2023 | 8958 | 0.600 |
Why?
| | Air Pollution | 1 | 2019 | 199 | 0.590 |
Why?
| | Cardiovascular Diseases | 5 | 2023 | 1795 | 0.590 |
Why?
| | Marijuana Abuse | 1 | 2019 | 208 | 0.590 |
Why?
| | Female | 96 | 2023 | 61261 | 0.580 |
Why?
| | Humans | 120 | 2024 | 118251 | 0.580 |
Why?
| | Male | 88 | 2023 | 57474 | 0.550 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 20 | 0.530 |
Why?
| | Vascular Calcification | 5 | 2019 | 123 | 0.530 |
Why?
| | Disease Progression | 24 | 2021 | 2477 | 0.520 |
Why?
| | Risk Assessment | 8 | 2019 | 3043 | 0.510 |
Why?
| | Aged | 38 | 2022 | 19594 | 0.480 |
Why?
| | Cohort Studies | 28 | 2023 | 5078 | 0.480 |
Why?
| | Adult | 50 | 2023 | 31324 | 0.430 |
Why?
| | Prospective Studies | 24 | 2023 | 6443 | 0.420 |
Why?
| | Atherosclerosis | 4 | 2023 | 345 | 0.400 |
Why?
| | Coronary Disease | 7 | 2010 | 355 | 0.400 |
Why?
| | Airway Obstruction | 2 | 2024 | 167 | 0.380 |
Why?
| | Emphysema | 2 | 2023 | 122 | 0.370 |
Why?
| | Pulmonary Artery | 4 | 2022 | 1055 | 0.370 |
Why?
| | Depression | 4 | 2022 | 1133 | 0.350 |
Why?
| | Prevalence | 12 | 2023 | 2321 | 0.340 |
Why?
| | Longitudinal Studies | 8 | 2023 | 2491 | 0.340 |
Why?
| | Lipoproteins | 3 | 2016 | 163 | 0.340 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 15 | 0.330 |
Why?
| | Vital Capacity | 6 | 2023 | 260 | 0.330 |
Why?
| | Albuminuria | 4 | 2016 | 196 | 0.330 |
Why?
| | Calcium | 7 | 2018 | 1151 | 0.320 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2659 | 0.320 |
Why?
| | Young Adult | 15 | 2023 | 10731 | 0.310 |
Why?
| | Bronchi | 3 | 2022 | 241 | 0.310 |
Why?
| | Metformin | 2 | 2021 | 293 | 0.310 |
Why?
| | Marijuana Use | 2 | 2021 | 157 | 0.300 |
Why?
| | Case-Control Studies | 14 | 2019 | 3156 | 0.290 |
Why?
| | Predictive Value of Tests | 10 | 2019 | 1857 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 7 | 2023 | 2262 | 0.290 |
Why?
| | Quality of Life | 4 | 2021 | 2355 | 0.280 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 418 | 0.280 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 136 | 0.280 |
Why?
| | Proportional Hazards Models | 6 | 2019 | 1124 | 0.270 |
Why?
| | Cross-Sectional Studies | 14 | 2024 | 4521 | 0.270 |
Why?
| | Cause of Death | 2 | 2018 | 379 | 0.260 |
Why?
| | Body Mass Index | 10 | 2022 | 2074 | 0.260 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 58 | 0.260 |
Why?
| | Antidepressive Agents | 3 | 2019 | 189 | 0.260 |
Why?
| | Biomarkers | 11 | 2022 | 3567 | 0.260 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 40 | 0.260 |
Why?
| | Artificial Intelligence | 2 | 2023 | 137 | 0.250 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 194 | 0.250 |
Why?
| | Follow-Up Studies | 11 | 2022 | 4574 | 0.250 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 301 | 0.250 |
Why?
| | Renal Insufficiency | 2 | 2016 | 150 | 0.250 |
Why?
| | United States | 10 | 2023 | 12488 | 0.240 |
Why?
| | Symptom Flare Up | 2 | 2021 | 40 | 0.240 |
Why?
| | Dyspnea | 5 | 2024 | 201 | 0.240 |
Why?
| | Logistic Models | 12 | 2017 | 1896 | 0.230 |
Why?
| | Multimorbidity | 1 | 2023 | 29 | 0.230 |
Why?
| | Aged, 80 and over | 9 | 2022 | 6541 | 0.230 |
Why?
| | Fibrinogen | 3 | 2014 | 150 | 0.230 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 58 | 0.220 |
Why?
| | Propofol | 2 | 2021 | 49 | 0.220 |
Why?
| | Adiponectin | 4 | 2016 | 224 | 0.220 |
Why?
| | Limit of Detection | 2 | 2019 | 55 | 0.220 |
Why?
| | Population Health | 1 | 2023 | 45 | 0.220 |
Why?
| | Umbilical Cord | 2 | 2021 | 84 | 0.210 |
Why?
| | Cannabidiol | 1 | 2023 | 53 | 0.210 |
Why?
| | Ketosis | 1 | 2022 | 13 | 0.210 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 73 | 0.210 |
Why?
| | Cystatin C | 3 | 2011 | 69 | 0.210 |
Why?
| | Cholesterol | 4 | 2011 | 375 | 0.210 |
Why?
| | Hallucinogens | 1 | 2023 | 74 | 0.200 |
Why?
| | Self Report | 3 | 2021 | 698 | 0.200 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 69 | 0.200 |
Why?
| | Protective Agents | 1 | 2021 | 41 | 0.200 |
Why?
| | Hand Strength | 2 | 2022 | 99 | 0.200 |
Why?
| | Sarcopenia | 1 | 2022 | 72 | 0.200 |
Why?
| | Antirheumatic Agents | 1 | 2023 | 254 | 0.200 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 84 | 0.190 |
Why?
| | Genome-Wide Association Study | 5 | 2023 | 1318 | 0.190 |
Why?
| | C-Reactive Protein | 2 | 2014 | 364 | 0.190 |
Why?
| | Muscular Atrophy | 1 | 2021 | 80 | 0.190 |
Why?
| | Hepatitis C | 1 | 2023 | 217 | 0.180 |
Why?
| | Delirium | 1 | 2021 | 68 | 0.180 |
Why?
| | 2-Propanol | 1 | 2019 | 21 | 0.180 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 6 | 0.180 |
Why?
| | Osteoporosis | 1 | 2022 | 226 | 0.180 |
Why?
| | Foam Cells | 1 | 2019 | 15 | 0.180 |
Why?
| | Hyperostosis | 1 | 2019 | 6 | 0.180 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 288 | 0.180 |
Why?
| | Calibration | 1 | 2019 | 134 | 0.180 |
Why?
| | Genetic Markers | 2 | 2019 | 347 | 0.170 |
Why?
| | Carbon Monoxide | 1 | 2019 | 64 | 0.170 |
Why?
| | Blood Glucose | 6 | 2022 | 1936 | 0.170 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 171 | 0.170 |
Why?
| | Regression Analysis | 6 | 2022 | 984 | 0.170 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 38 | 0.170 |
Why?
| | Adipose Tissue | 2 | 2017 | 595 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 136 | 0.160 |
Why?
| | Surface Properties | 1 | 2019 | 397 | 0.160 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 464 | 0.160 |
Why?
| | Diabetes Complications | 2 | 2010 | 218 | 0.160 |
Why?
| | Drug Overdose | 1 | 2022 | 293 | 0.160 |
Why?
| | Insulin Resistance | 4 | 2017 | 1167 | 0.160 |
Why?
| | Heart Ventricles | 2 | 2020 | 725 | 0.160 |
Why?
| | Vascular Remodeling | 1 | 2019 | 150 | 0.160 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 268 | 0.160 |
Why?
| | Population Surveillance | 1 | 2021 | 413 | 0.150 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 211 | 0.150 |
Why?
| | Organ Size | 4 | 2021 | 460 | 0.150 |
Why?
| | HIV Infections | 2 | 2023 | 2454 | 0.150 |
Why?
| | Environmental Monitoring | 1 | 2019 | 295 | 0.150 |
Why?
| | Urine | 1 | 2017 | 58 | 0.150 |
Why?
| | Linear Models | 6 | 2019 | 817 | 0.150 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 641 | 0.150 |
Why?
| | Phenotype | 4 | 2019 | 2937 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2023 | 465 | 0.150 |
Why?
| | Chronic Disease | 1 | 2023 | 1630 | 0.150 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 35 | 0.150 |
Why?
| | Obesity | 4 | 2022 | 2715 | 0.140 |
Why?
| | Lung Diseases | 1 | 2023 | 709 | 0.140 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 20 | 0.140 |
Why?
| | Prenatal Care | 1 | 2019 | 252 | 0.140 |
Why?
| | Machine Learning | 1 | 2019 | 321 | 0.140 |
Why?
| | Anxiety | 2 | 2022 | 845 | 0.140 |
Why?
| | Blood Pressure | 5 | 2023 | 1656 | 0.140 |
Why?
| | Plasma | 1 | 2017 | 194 | 0.140 |
Why?
| | Comorbidity | 5 | 2021 | 1516 | 0.130 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 16 | 0.130 |
Why?
| | Aortography | 1 | 2015 | 52 | 0.130 |
Why?
| | Respiratory System | 1 | 2016 | 141 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 990 | 0.130 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1469 | 0.130 |
Why?
| | Dexmedetomidine | 1 | 2015 | 52 | 0.130 |
Why?
| | Exercise Tolerance | 3 | 2023 | 234 | 0.130 |
Why?
| | Periodontal Diseases | 1 | 2015 | 58 | 0.130 |
Why?
| | Evoked Potentials | 1 | 2015 | 115 | 0.130 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 156 | 0.120 |
Why?
| | Adiposity | 2 | 2022 | 508 | 0.120 |
Why?
| | Respiratory Muscles | 1 | 2014 | 36 | 0.120 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2015 | 33 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 2057 | 0.120 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 890 | 0.120 |
Why?
| | Health Status | 2 | 2022 | 723 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2019 | 447 | 0.120 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 78 | 0.120 |
Why?
| | Body Composition | 4 | 2021 | 644 | 0.120 |
Why?
| | Spine | 1 | 2015 | 144 | 0.120 |
Why?
| | Heart | 1 | 2017 | 630 | 0.120 |
Why?
| | Aorta | 1 | 2015 | 364 | 0.110 |
Why?
| | Up-Regulation | 1 | 2016 | 862 | 0.110 |
Why?
| | Sex Distribution | 5 | 2014 | 347 | 0.110 |
Why?
| | Colorado | 6 | 2021 | 4178 | 0.110 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 225 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 500 | 0.100 |
Why?
| | Registries | 1 | 2019 | 1806 | 0.100 |
Why?
| | Triglycerides | 2 | 2011 | 515 | 0.100 |
Why?
| | Haptoglobins | 1 | 2011 | 49 | 0.100 |
Why?
| | Blood Vessels | 1 | 2013 | 187 | 0.100 |
Why?
| | Occupational Exposure | 1 | 2014 | 275 | 0.100 |
Why?
| | Reference Values | 4 | 2023 | 770 | 0.100 |
Why?
| | Adolescent | 6 | 2022 | 18364 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1784 | 0.100 |
Why?
| | Alcohol Drinking | 2 | 2009 | 651 | 0.100 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2023 | 68 | 0.090 |
Why?
| | Walk Test | 2 | 2021 | 49 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2021 | 12929 | 0.090 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 8 | 0.090 |
Why?
| | Coma | 1 | 2009 | 32 | 0.090 |
Why?
| | Patient Education as Topic | 2 | 2005 | 696 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2017 | 512 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 400 | 0.090 |
Why?
| | Facial Nerve | 1 | 2009 | 32 | 0.090 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 26 | 0.090 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 43 | 0.090 |
Why?
| | Aortic Diseases | 1 | 2010 | 94 | 0.090 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 18 | 0.090 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 31 | 0.090 |
Why?
| | Hypertension | 5 | 2015 | 1199 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1787 | 0.090 |
Why?
| | Reproducibility of Results | 5 | 2017 | 2855 | 0.080 |
Why?
| | Airway Remodeling | 2 | 2021 | 57 | 0.080 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 32 | 0.080 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 81 | 0.080 |
Why?
| | Surveys and Questionnaires | 7 | 2019 | 4684 | 0.080 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 12 | 0.080 |
Why?
| | Kidney | 1 | 2016 | 1351 | 0.080 |
Why?
| | Odds Ratio | 4 | 2014 | 993 | 0.080 |
Why?
| | Proteinuria | 1 | 2009 | 99 | 0.080 |
Why?
| | Sex Factors | 4 | 2020 | 1765 | 0.080 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.080 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 248 | 0.080 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 8 | 0.080 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.080 |
Why?
| | Coronary Angiography | 2 | 2014 | 311 | 0.080 |
Why?
| | Asthma | 1 | 2021 | 2143 | 0.080 |
Why?
| | Face | 1 | 2009 | 164 | 0.080 |
Why?
| | Radiography | 3 | 2016 | 860 | 0.080 |
Why?
| | Inflammation | 2 | 2021 | 2545 | 0.080 |
Why?
| | Prognosis | 4 | 2021 | 3424 | 0.070 |
Why?
| | Uric Acid | 1 | 2010 | 349 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 431 | 0.070 |
Why?
| | Time Factors | 6 | 2015 | 6368 | 0.070 |
Why?
| | Heart Rate | 1 | 2010 | 729 | 0.070 |
Why?
| | Mortality | 2 | 2019 | 297 | 0.070 |
Why?
| | Dietary Fats | 1 | 2009 | 323 | 0.070 |
Why?
| | Incidence | 3 | 2019 | 2413 | 0.070 |
Why?
| | Contraception | 1 | 2008 | 117 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 82 | 0.070 |
Why?
| | Apolipoproteins A | 1 | 2006 | 18 | 0.070 |
Why?
| | Apolipoproteins C | 1 | 2006 | 6 | 0.070 |
Why?
| | Propensity Score | 2 | 2019 | 242 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 439 | 0.070 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 65 | 0.070 |
Why?
| | Cluster Analysis | 2 | 2019 | 479 | 0.070 |
Why?
| | Internationality | 2 | 2017 | 152 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 387 | 0.070 |
Why?
| | Receptors, IgG | 1 | 2005 | 67 | 0.070 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 524 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 436 | 0.060 |
Why?
| | Pregnancy | 3 | 2023 | 5671 | 0.060 |
Why?
| | Abdominal Wall | 1 | 2004 | 27 | 0.060 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 12 | 0.060 |
Why?
| | Haplotypes | 1 | 2006 | 474 | 0.060 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 681 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 316 | 0.060 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 194 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 360 | 0.060 |
Why?
| | Insulin | 3 | 2022 | 2157 | 0.060 |
Why?
| | Antigens, CD | 1 | 2005 | 457 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 232 | 0.050 |
Why?
| | Blood Platelets | 1 | 2005 | 344 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 126 | 0.050 |
Why?
| | Genotype | 3 | 2018 | 1870 | 0.050 |
Why?
| | Multifactorial Inheritance | 1 | 2023 | 143 | 0.050 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 163 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 293 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 332 | 0.050 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 46 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2021 | 21 | 0.050 |
Why?
| | Reaction Time | 2 | 2015 | 390 | 0.050 |
Why?
| | Child, Preschool | 3 | 2023 | 9448 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1262 | 0.050 |
Why?
| | Hepacivirus | 1 | 2023 | 230 | 0.050 |
Why?
| | Protective Factors | 1 | 2021 | 90 | 0.050 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 32 | 0.050 |
Why?
| | Plethysmography | 1 | 2021 | 124 | 0.050 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 63 | 0.050 |
Why?
| | Anesthesia, General | 1 | 2021 | 48 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2021 | 129 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 939 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2022 | 341 | 0.050 |
Why?
| | Cigarette Smoking | 1 | 2021 | 79 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2021 | 9319 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2021 | 165 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 504 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | Lipids | 2 | 2017 | 591 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 8 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 46 | 0.040 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 27 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 568 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 463 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1288 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 43 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 652 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 251 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 1647 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 447 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 668 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 387 | 0.040 |
Why?
| | Europe | 1 | 2019 | 355 | 0.040 |
Why?
| | Systems Biology | 1 | 2018 | 57 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 964 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 19 | 0.040 |
Why?
| | Maternal Health Services | 1 | 2019 | 83 | 0.040 |
Why?
| | Electrocardiography | 2 | 2010 | 555 | 0.040 |
Why?
| | Electric Impedance | 1 | 2017 | 99 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 517 | 0.040 |
Why?
| | Total Lung Capacity | 1 | 2016 | 33 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 294 | 0.040 |
Why?
| | Michigan | 1 | 2017 | 95 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 940 | 0.040 |
Why?
| | Bronchial Arteries | 1 | 2016 | 11 | 0.040 |
Why?
| | Causality | 1 | 2017 | 109 | 0.040 |
Why?
| | RNA | 1 | 2023 | 830 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 840 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 408 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 293 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 482 | 0.030 |
Why?
| | Cough | 1 | 2016 | 102 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1026 | 0.030 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 31 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2015 | 37 | 0.030 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 34 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 307 | 0.030 |
Why?
| | Automation | 1 | 2015 | 76 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 283 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 231 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 470 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 667 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 248 | 0.030 |
Why?
| | Stroke | 1 | 2003 | 1046 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 171 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1338 | 0.030 |
Why?
| | Mice | 2 | 2021 | 15446 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 497 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 93 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2015 | 162 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 962 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2664 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 185 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4887 | 0.030 |
Why?
| | Vascular Stiffness | 1 | 2017 | 425 | 0.030 |
Why?
| | Exercise Test | 1 | 2014 | 552 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 329 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1683 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 511 | 0.020 |
Why?
| | Median Nerve | 1 | 2009 | 21 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 109 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 586 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 17 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 89 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 125 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 306 | 0.020 |
Why?
| | Animals | 2 | 2021 | 33152 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 134 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 353 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 2990 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 78 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1522 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 453 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 326 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 11 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 22 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 465 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 65 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 55 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 332 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 160 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 670 | 0.020 |
Why?
| | Self Care | 1 | 2009 | 356 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 275 | 0.020 |
Why?
| | Hospitalization | 1 | 2014 | 1778 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 31 | 0.020 |
Why?
| | Platelet Aggregation | 1 | 2005 | 93 | 0.020 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 32 | 0.020 |
Why?
| | Age Distribution | 1 | 2005 | 358 | 0.020 |
Why?
| | Anthropometry | 1 | 2004 | 192 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2009 | 595 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 829 | 0.010 |
Why?
| | Neoplasms | 1 | 2016 | 2160 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1072 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1157 | 0.010 |
Why?
| | Risk | 1 | 2003 | 849 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 313 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1167 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1385 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2009 | 2230 | 0.010 |
Why?
| | Child | 1 | 2017 | 19033 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1031 | 0.010 |
Why?
| | Infant | 1 | 2009 | 8254 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|